4 stories mentioning ASX:NANUpdated 3h ago
Every FINWIRES story that references ASX:NAN, newest first.
Nanosonics (ASX:NAN) launched a new on-market share buyback of up to AU$40 million in fiscal 2027, after a AU$20 million share buyback was completed in fiscal 2026, according to a Tuesday filing with the Australian bourse.Shares fell nearly 23% in morning trade Tuesday.
Nanosonics (ASX:NAN) logged AU$0.0577 in EPS for 2026, compared with AU$0.0669 a year ago, a Tuesday filing showed.For the 12 months ended June 30, revenue was AU$203.9 million versus AU$198.6 million previously, the Australia-listed healthcare company added.The company expects 2027 revenue in the range of AU$220 million to AU$228 million.
Nanosonics (ASX:NAN) received notice that JPMorgan Chase and its affiliates are no longer substantial holders of the company from May 27, according to a Monday filing with the Australian bourse.JPMorgan Chase and its affiliates became a substantial holder of the company on May 26, with a total voting power of 5.04%, an earlier filing showed.The company's shares rose 2% in recent Monday trade.
Nanosonics (ASX:NAN) advanced the staged rollout of its CORIS system by submitting a second application to the US food and drug administration aimed at broadening approved endoscope indications following its earlier clearance, according to a Tuesday filing with the Australian bourseThe company is also progressing its controlled market release (CMR) program, having installed its first CORIS unit in Australia and started staff training in preparation for a planned rollout, per the filing.The United Kingdom CMR is ongoing and performing as expected, with Australia and Ireland sites rolling out next and US activities to follow based on early learnings, the filing added.
